8800465156



**PATIENT NAME: PAYAL PARIHAR 158513** REF. DOCTOR: DR. BOB PKG

CODE/NAME & ADDRESS : C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : PAYAF02039561

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 02/03/2024 11:27:48 DELHI ABHA NO REPORTED :05/03/2024 15:18:08 **NEW DELHI 110030** 

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

н	IAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	12.5	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT	4.51	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT	9.15	4.0 - 10.0	thou/µL
PLATELET COUNT	382	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	39.9	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV)	88.5	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.7	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.3 Low	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	13.4	11.6 - 14.0	%
MENTZER INDEX	19.6		
MEAN PLATELET VOLUME (MPV)	9.3	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	66	40 - 80	%
LYMPHOCYTES	30	20 - 40	%
MONOCYTES	03	2 - 10	%
EOSINOPHILS	01	1 - 6	%

# Interpretation(s)

**BASOPHILS** 

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

< 1 - 2

00

Dr. Tarun Sharma **Consultant Pathologist**  Dr. Itisha Dhiman **Pathologist** 





Page 1 Of 17

## **PERFORMED AT:**

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India

Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email: srl.jodhpur@gmail.com



%

8800465156



PATIENT NAME: PAYAL PARIHAR 158513 REF. DOCTOR: DR. BOB PKG

CODE/NAME & ADDRESS : C000138375 ACCESSION NO : **0061XC000114** AGE/SEX : 29 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PAVAED2020E61 DRAWN) .

F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED : 02/03/2024 11:27:48

NEW DELHI 110030 REPORTED : 05/03/2024 15:18:08

Test Report Status <u>Final</u> Results Biological Reference Interval Units

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Tarun Sharma Consultant Pathologist Dr. Itisha Dhiman Pathologist





Page 2 Of 17

View Details

View Report

# PERFORMED AT :

Agilus Diagnostics Ltd. M/S S.S. Wellness Centre,Ground Floor,C-22,Shastri Nagar,Near Central Academy School Jodhpur, 342001

Rajasthan, India





REF. DOCTOR: DR. BOB PKG **PATIENT NAME: PAYAL PARIHAR 158513** 

CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

PATIENT ID : PAYAF02039561

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 02/03/2024 11:27:48 REPORTED :05/03/2024 15:18:08

**Test Report Status Biological Reference Interval Final** Results Units

#### **HAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

#### **ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD**

60 High 0 - 20mm at 1 hr E.S.R

METHOD: WESTERGREN METHOD

## GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 5.3 Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5

ADA Target: 7.0 Action suggested: > 8.0

ESTIMATED AVERAGE GLUCOSE(EAG) 105.4 < 116.0 mg/dL

#### Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

## TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

#### **LIMITATIONS**

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

# REFERENCE:

. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr. Itisha Dhiman **Pathologist** 

Dr. Tarun Sharma **Consultant Pathologist** 





Page 3 Of 17

View Report

## **PERFORMED AT:**

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India





REF. DOCTOR: DR. BOB PKG **PATIENT NAME: PAYAL PARIHAR 158513** 

CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL DRAWN

PATIENT ID : PAYAF02039561 F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 02/03/2024 11:27:48 DELHI ABHA NO REPORTED :05/03/2024 15:18:08 **NEW DELHI 110030** 8800465156

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
   eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

- **HbA1c Estimation can get affected due to :**1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test résults.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
  3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

  4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy, Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Itisha Dhiman

**Pathologist** 

Dr. Tarun Sharma **Consultant Pathologist** 



Page 4 Of 17

View Report



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PAYAF02039561

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

CLIENT PATIENT ID: ABHA NO

Female

RECEIVED: 02/03/2024 11:27:48 REPORTED :05/03/2024 15:18:08

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

#### **IMMUNOHAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

## **ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

TYPE O **ABO GROUP** 

METHOD: FORWARD/REVERSE

**POSITIVE** RH TYPE

METHOD: FORWARD/REVERSE

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Tarun Sharma **Consultant Pathologist**  Dr. Itisha Dhiman

**Pathologist** 





Page 5 Of 17



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0061XC000114

PATIENT ID : PAYAF02039561

CLIENT PATIENT ID: ABHA NO

AGE/SEX : 29 Years Female

RECEIVED: 02/03/2024 11:27:48 REPORTED :05/03/2024 15:18:08

**Test Report Status** Results Biological Reference Interval Units <u>Final</u>

**BIOCHEMISTRY** 

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)

Normal : < 100

mg/dL

Pre-diabetes: 100-125 Diabetes: >/=126

METHOD: SPECTROPHOTOMETRY

METHOD: SPECTROPHOTOMETRY

**GLUCOSE, POST-PRANDIAL, PLASMA** 

PPBS(POST PRANDIAL BLOOD SUGAR)

104

94

70 - 140

mg/dL

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL

METHOD: SPECTROPHOTOMETRY

168

64

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

< 150 Normal

150 - 199 Borderline High

200 - 499 High

>/=500 Very High

METHOD: SPECTROPHOTOMETRY

HDL CHOLESTEROL

TRIGLYCERIDES

52

< 40 Low

mg/dL

mg/dL

>/=60 High

METHOD: SPECTROPHOTOMETRY

CHOLESTEROL LDL

103 High

< 100 Optimal

mg/dL

100 - 129

Near optimal/ above optimal

130 - 159 Borderline High 160 - 189 High

>/= 190 Very High

Dr. Tarun Sharma **Consultant Pathologist**  Dr. Itisha Dhiman

**Pathologist** 



Page 6 Of 17



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India



NEW DELHI 110030 8800465156



REPORTED :05/03/2024 15:18:08

PATIENT NAME: PAYAL PARIHAR 158513

REF. DOCTOR: DR. BOB PKG

CODE/NAME & ADDRESS: C000138375

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI CLIENT PATIENT ID: RECEIVED: 02/03/2024 11:27:48

ABHA NO

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u> NON HDL CHOLESTEROL mg/dL 116 Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220 VERY LOW DENSITY LIPOPROTEIN 12.8 </=30.0mg/dL CHOL/HDL RATIO 3.2 Low 3.3 - 4.4Low Risk 4.5 - 7.0Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk LDL/HDL RATIO 2.0 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate

Risk

>6.0 High Risk

# Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	`	, · · ·	
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 i	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use			
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Dr. Tarun Sharma Consultant Pathologist Dr. Itisha Dhiman Pathologist





Page 7 Of 17



View Report

## **PERFORMED AT:**

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India





CODE/NAME & ADDRESS : C000138375 ACCESSION NO : **0061XC000114** AGE/SEX : 29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL | PAYAF02039561 | DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI RECEIVED : 02/03/2024 11:27:48

Test Report Status Final Results Biological Reference Interval Units

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

tewer treatment goals and statin initiation thresholds based on the risk categories proposed by 12.11 in 2020.				
Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30 )	< 80 (Optional goal <or 60)<="" =="" td=""><td>&gt;OR = 50</td><td>&gt;OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

**References:** Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

## LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	1.00	0.2 - 1.0	mg/dL
METHOD: SPECTROPHOTOMETRY BILIRUBIN, DIRECT	0.10	0.0 - 0.2	mg/dL
METHOD: SPECTROPHOTOMETRY BILIRUBIN, INDIRECT	0.90	0.1 - 1.0	mg/dL
METHOD: SPECTROPHOTOMETRY  TOTAL PROTEIN	7.9	6.4 - 8.2	g/dL
METHOD: SPECTROPHOTOMETRY  ALBUMIN	4.5	3.4 - 5.0	g/dL
METHOD: SPECTROPHOTOMETRY  GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.3	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER  ASPARTATE AMINOTRANSFERASE(AST/SGOT)  METHOD: SPECTROPHOTOMETRY	17	15 - 37	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	34	< 34.0	U/L
METHOD: SPECTROPHOTOMETRY  ALKALINE PHOSPHATASE  METHOD: SPECTROPHOTOMETRY	74	30 - 120	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	26	5 - 55	U/L
METHOD: SPECTROPHOTOMETRY  LACTATE DEHYDROGENASE  METHOD: SPECTROPHOTOMETRY	149	81 - 234	U/L

I.

Dr. Tarun Sharma Consultant Pathologist gua.

Dr. Itisha Dhiman Pathologist





Page 8 Of 17

View Details

View Report

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHÍ

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female PATIENT ID

: PAYAF02039561

CLIENT PATIENT ID: ABHA NO

RECEIVED : 02/03/2024 11:27:48 REPORTED :05/03/2024 15:18:08

	i	İ	
Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: SPECTROPHOTOMETRY	11	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE  METHOD: SPECTROPHOTOMETRY	0.61	0.60 - 1.10	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO  METHOD: SPECTROPHOTOMETRY	18.03 High	5.00 - 15.00	
URIC ACID, SERUM			
URIC ACID  METHOD: SPECTROPHOTOMETRY	2.5 Low	2.6 - 6.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN  METHOD: SPECTROPHOTOMETRY	7.9	6.4 - 8.2	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD: SPECTROPHOTOMETRY	4.5	3.4 - 5.0	g/dL
GLOBULIN			
GLOBULIN METHOD: CALCULATED PARAMETER	3.4	2.0 - 4.1	g/dL

Dr. Tarun Sharma **Consultant Pathologist** 

Dr. Itisha Dhiman **Pathologist** 





Page 9 Of 17

# **PERFORMED AT:**

Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

PATIENT ID : PAYAF02039561

CLIENT PATIENT ID: ABHA NO

RECEIVED: 02/03/2024 11:27:48

REPORTED :05/03/2024 15:18:08

mmol/L

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

## **ELECTROLYTES (NA/K/CL), SERUM**

SODIUM, SERUM 138 136 - 145 mmol/L

METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY

POTASSIUM, SERUM 3.50 - 5.10 5.1

METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY

111 High 98 - 107 mmol/L CHLORIDE, SERUM

METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY

### Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre no corticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Dr. Tarun Sharma **Consultant Pathologist** 

Dr. Itisha Dhiman **Pathologist** 





Page 10 Of 17

# **PERFORMED AT:**

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India





Female

REF. DOCTOR: DR. BOB PKG **PATIENT NAME: PAYAL PARIHAR 158513** 

CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

ACCESSION NO : 0061XC000114

PATIENT ID : PAYAF02039561

CLIENT PATIENT ID: ABHA NO

AGE/SEX

RECEIVED: 02/03/2024 11:27:48

:29 Years

REPORTED: 05/03/2024 15:18:08

**Test Report Status** Results **Biological Reference Interval** Units **Final** 

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis,

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease,high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein,is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstrom disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc.
ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Tarun Sharma **Consultant Pathologist** 

Dr. Itisha Dhiman Pathologist



Page 11 Of 17

View Report

# **PERFORMED AT:**

Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX : 29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PAYAF02039561

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 02/03/2024 11:27:48 DELHI ABHA NO REPORTED :05/03/2024 15:18:08 **NEW DELHI 110030** 8800465156

**Test Report Status** Results Biological Reference Interval Units <u>Final</u>

#### **CLINICAL PATH - URINALYSIS**

### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

**COLOR** PALE YELLOW

**APPEARANCE CLEAR** 

# **CHEMICAL EXAMINATION, URINE**

PH	5.5	4.7 - 7.5
SPECIFIC GRAVITY	1.005	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

# MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	5-7	0-5	/HPF

NOT DETECTED **CASTS** NOT DETECTED **CRYSTALS** 

BACTERIA DETECTED NOT DETECTED

(OCCASIONAL)

METHOD: MICROSCOPIC EXAMINATION

**NOT DETECTED** NOT DETECTED YEAST

Dr. Tarun Sharma **Consultant Pathologist** 

Dr. Itisha Dhiman **Pathologist** 





Page 12 Of 17





Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





CODE/NAME & ADDRESS : C000138375 ACCESSION NO : **0061XC000114** AGE/SEX : 29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PAYAF02039561

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 02/03/2024 11:27:48

DELHI

NEW DELHI 110030

ABHA NO : RECEIVED : 02/03/2024 11:27:48

REPORTED : 05/03/2024 15:18:08

Test Report Status <u>Final</u> Results Biological Reference Interval Units

# Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind	
	of kidney impairment	
Glucose	Diabetes or kidney disease	
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst	
Urobilinogen	Liver disease such as hepatitis or cirrhosis	
Blood	Renal or genital disorders/trauma	
Bilirubin	Liver disease	
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases	
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions	
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time	
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein	
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases	
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice	
Uric acid	arthritis	
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis	

Dr. Tarun Sharma Consultant Pathologist Dr. Itisha Dhiman Pathologist



Page 13 Of 17







Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

PATIENT ID : PAYAF02039561

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 02/03/2024 11:27:48 REPORTED :05/03/2024 15:18:08

**Test Report Status** Results Biological Reference Interval Units <u>Final</u>

#### **CYTOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

#### **PAPANICOLAOU SMEAR**

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

TWO UNSTAINED CERVICAL SMEARS RECEIVED SPECIMEN TYPE

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY REPORTING SYSTEM

SPECIMEN ADEQUACY SATISFACTORY

SMEARS SHOW SUPERFICIAL AND INTERMEDIATE SQUAMOUS **MICROSCOPY** 

CELLS SHOWING MILD TO MODERATE REACTIVE CHANGES OF

INFLAMMATION.

BACKGROUND SHOW BACILLARY AGGREGRATES AND MODERATE DEGREE OF ACUTE INFLMMATION PREDOMINANTLY COMPRISING OF

NEUTROPHILS.

ENDOCERVICAL COMPONENT ABSENT. NO ATYPICAL CELLS SEEN.

METHOD: MANUAL

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY INTERPRETATION / RESULT

#### **LETTER**

ADDITIONAL COMMUNICATION

ADV- ANTIBIOTIC AND ANTI INFLAMMATORY THERAPY AS PER

CLINICIAN'S ADVICE.

Dr. Tarun Sharma

Dr. Itisha Dhiman **Pathologist** 







Page 14 Of 17



**Consultant Pathologist** 

Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

PATIENT ID : PAYAF02039561

CLIENT PATIENT ID: ABHA NO

RECEIVED: 02/03/2024 11:27:48 REPORTED: 05/03/2024 15:18:08

**Test Report Status** Biological Reference Interval Results Units **Final** 

#### **SPECIALISED CHEMISTRY - HORMONE**

## MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM		
Т3	122.20	Non-Pregnant Women ng/dL 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0
T4	8.32	Non-Pregnant Women µg/dL 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70
TSH (ULTRASENSITIVE)	2.200	Non Pregnant Women µIU/mL 0.27 - 4.20 Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

### Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Total T4 FT4 Total T3 **Possible Conditions** 

Dr. Itisha Dhiman **Pathologist** 

Dr. Tarun Sharma **Consultant Pathologist** 



Page 15 Of 17



Jodhpur, 342001

Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

CIN - U74899PB1995PLC045956 Email: srl.jodhpur@gmail.com

Rajasthan, India Tel: 0291-2646000, 2644000, Fax:





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC000114 AGE/SEX :29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PAYAF02039561

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 02/03/2024 11:27:48 DELHI ABHA NO REPORTED :05/03/2024 15:18:08 **NEW DELHI 110030** 8800465156

**Test Report Status Final** Results **Biological Reference Interval** Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> \*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Itisha Dhiman **Pathologist** 

Dr. Tarun Sharma **Consultant Pathologist** 





Page 16 Of 17







Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





REF. DOCTOR: DR. BOB PKG **PATIENT NAME: PAYAL PARIHAR 158513** 

CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0061XC000114

PATIENT ID : PAYAF02039561

CLIENT PATIENT ID: ABHA NO

AGE/SEX

:29 Years Female

RECEIVED: 02/03/2024 11:27:48 REPORTED :05/03/2024 15:18:08

**Test Report Status** Results Biological Reference Interval Units **Final** 

### **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

## **Agilus Diagnostics Ltd**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Itisha Dhiman **Pathologist** 

Dr. Tarun Sharma **Consultant Pathologist**  Page 17 Of 17









Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India Tel: 0291-2646000, 2644000, Fax:

CIN - U74899PB1995PLC045956 Email: srl.jodhpur@gmail.com

